AzTrials
AzTrials

Solid TumorPhase 1/2NCT07698587

A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors

A Phase 1/2 study testing BM230 & PD-1 inhibitor in people with Solid Tumor, run by Suzhou Biomissile Pharmaceuticals Co., Ltd. at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a multicenter, non-randomized, open-label, Phase Ib/II combination therapy trial. The trial consists of two parts: Part 1 (Phase Ib), dose-escalation of combination therapy, followed by Part 2 (Phase II), tumor-type exploration of combination therapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumor
What is being tested?
BM230 & PD-1 inhibitor
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteChina
Study dates
Nov 2026to Dec 2029
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • common inclusion criteria (Phase Ib and Phase II) (Criteria 1 to 10)
  • Informed of the study before the start of the study and voluntarily sign their name and date on the informed consent form (ICF)
  • Males and Females≥18 years old（at the time consent is obtained）
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1
  • Life expectancy of ≥ 3 months
  • Adequate organ and bone marrow function, defined as:
Show all 26Show fewer
  • Bone marrow function: hemoglobin ≥ 90 g/L (have not received blood transfusion or erythropoietin treatment within 14 days before the first dose); absolute neutrophil count ≥ 1.5×109/L (have not received granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor treatment within 14 days before the first dose); platelet count ≥ 100×109/L ((have not received platelet transfusion, thrombopoietin, or interleukin-11 treatment within 14 days before the first dose)
  • Coagulation function: activated partial thromboplastin time and international normalized ratio ≤ 1.5 × ULN
  • Liver function (based on the normal range at the study site): TBIL ≤ 1.5 × ULN if no demonstrable liver lesion(s) (primary or metastases), < 4 × ULN for patients with Gilbert syndrome, or ≤ 3 × ULN in the presence of liver lesion(s); ALT and AST ≤ 3 × ULN if no demonstrable liver lesion(s) (primary or metastases), or ≤ 5 × ULN in the presence of liver lesion(s)
  • Renal function (based on the normal range at the study site): creatinine clearance (CrCl) calculated by the Cockcroft-Gault formula ≥ 50 mL/min, or 24-h urine CrCl ≥ 50 mL/min
  • Cardiac function: LVEF ≥ 50%
  • Female patients of childbearing potential must agree to use a highly effective form of contraception and not donate, or retrieve for their own use, ova from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug; a negative pregnancy test must be obtained within 7 days before the first dose. Male patients must agree to use a highly effective form of contraception and not freeze or donate sperm from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug
  • Able and willing to comply with protocol visits and procedures
  • Have HER2 expression (IHC 1+, 2+, or 3+) determined by immunohistochemistry, or HER2 amplification (NGS report indicating HER2 amplification), or (for NSCLC) HER2 exon 8, exon 19, or exon 20 mutations. For Australia, only patients with cancer types covered by Australian Medicare for HER2 expression, amplification, or mutation testing, and/or patients with known HER2 expression, amplification, or mutation identified via any other program are to be considered
  • Willing to provide archived or fresh tumor tissue samples. Patients who are unable to provide tumor samples or have insufficient samples may be eligible on a case-by-case basis after discussion with the sponsor
  • Have at least 1 measurable target tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Additional inclusion criteria for Phase II (Criteria 11 to 14)
  • Cohort A: Unresectable or metastatic high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) advanced solid tumors in adult patients:
  • Patients with advanced colorectal cancer who have experienced disease progression following prior treatment with fluoropyrimidines, oxaliplatin, and irinotecan
  • Patients with other advanced solid tumors who have experienced disease progression after prior treatment and for whom no satisfactory alternative treatment is available
  • Cohort B: Esophageal squamous cell carcinoma:
  • Locally advanced or metastatic esophageal squamous cell carcinoma that has progressed or is intolerant following first-line standard chemotherapy
  • Cohort C: Urothelial carcinoma:
  • Locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, or after failure of platinum-based chemotherapy
  • Other tumor types:
  • Locally advanced or metastatic advanced solid tumors that have progressed or are intolerant following first-line standard chemotherapy, including cholangiocarcinoma, endometrial carcinoma, cervical cancer, ovarian cancer, etc

Who cannot join

  • Patients who meet any of the following criteria will NOT be included in the study:
  • Have received prior treatment with anti-HER2 antibody agents (excluding HER2 ADC agents).
  • Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive therapy for more than 28 days within the last 3 years, or clinically relevant immuno-deficiency diseases (eg, agammaglobulinemia or congenital
  • Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors (including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery)
  • Insufficient washout period of the prior anticancer treatment before the first dose of the investigational product, defined as follows:
  • Anti-neoplastic treatments such as chemotherapy, biological therapy, endocrine therapy and immunotherapy within 3 weeks before the first dose
Show all 37Show fewer
  • Palliative radiotherapy for tumors within 2 weeks before the first dose
  • Endocrine therapy for tumors within 2 weeks before the first dose
  • Chinese herbal medicine or Chinese patent medicine for tumor indications within 2 weeks before the first dose
  • Other unmarketed investigational drugs or treatments within 4 weeks before the first dose (fluoropyrimidines and small-molecule targeted drugs: within 2 weeks before the first dose or within 5 half-lives of the drug, whichever is shorter)
  • Undergone major surgery (not including diagnostic surgery) within 4 weeks before the first dose or are expected to undergo major surgery during the study
  • Has a history of allogeneic hematopoietic stem cell transplantation or organ transplantation
  • Received systemic corticosteroids (defined as > 10 mg/day of prednisone or equivalent) or other immuno-suppressive therapy within 2 weeks before the first dose. The following are exceptions to this criterion:
  • Intranasal, inhaled, topical steroids, topical corticosteroids or local steroid injections (eg, intra-articular injections)
  • Systemic steroids at physiological doses as replacement therapy (eg, physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency)
  • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
  • Received any live vaccines within 4 weeks before the first dose or intend to receive live vaccines during the study
  • Have experienced any Grade ≥3 immune-related adverse event (irAE), or a Grade <3 immune-related adverse event that occurred within 6 months prior to enrollment and has not yet resolved.
  • A history of leptomeningeal disease; or presence of unstable central nervous system (CNS) metastases. Stability is defined as having undergone surgical resection and/or radiation therapy for CNS metastases at least 28 days before the first dose, and meeting all of the following criteria after completion of treatment:
  • No neurological symptoms, or symptoms are stable and ≤ Grade 1
  • No progression of treated lesions and no new lesions on contrast-enhanced CT or MRI within 28 days before the first dose
  • No or mild cerebral edema on imaging at screening, without requirement for systemic corticosteroids or anticonvulsants
  • Uncontrolled or clinically significant cardiovascular disease, including but not limited to:
  • History of symptomatic CHF (New York Heart Association [NYHA] class II-IV) or any arterial thromboembolic events (e.g., myocardial infarction, unstable angina, cerebrovascular accident, transient ischaemic attack) within 6 months before the first dose
  • Uncontrolled hypertension, defined as systolic blood pressure (SBP) >160 mmHg and/or diastolic blood pressure (DBP) >100 mmHg despite antihypertensive therapy
  • Serious cardiac arrhythmia requiring treatment
  • The QT interval corrected by the Fridericia formula (QTcF) is prolonged to > 470 ms
  • Active haemorrhage with significant clinical significance
  • Uncontrolled third-space fluid (eg, pleural effusions, ascites, pericardial effusions) that requires repeated drainage
  • Uncontrolled or unstable systemic diseases, including diabetes mellitus, hepatic cirrhosis, interstitial lung disease, and obstructive lung disease, by the investigator's discretion
  • Uncontrolled infection that requires systemic therapy within 1 week before the first dose
  • Active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection. Active HBV is defined as hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) positive, and HBV DNA level above ULN at the study site; active HCV is defined as positive hepatitis C antibody and HCV RNA level above ULN at the study site; active HIV is defined as positive HIV antibody; active syphilis is defined as positive Treponema pallidum laboratory test. However, patients with well-controlled HIV (as judged by the investigator) may be considered eligible
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI CTCAE Grade ≤1, baseline, or the level specified in the inclusion/exclusion criteria with the exception of alopecia (any grade), pigmentation (any grade), and peripheral neuropathy (Grade ≤2). Patients with irreversible toxicity (eg, hearing loss) that is reasonably not expected to be aggravated by the study drug can be enrolled after discussion with the sponsor
  • A history of severe hypersensitivity reactions to the drug substances, inactive ingredients in the drug product, or other mAbs
  • Has a history of ≥ Grade 3 hypersensitivity or allergic reaction to IgG4 monoclonal antibodies and/or their excipients, or to the PD-1 inhibitor used in the corresponding cohort and/or its excipients.
  • Women who are breastfeeding or pregnant as confirmed by pregnancy tests performed within 7 days before the first dose
  • Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Rui Liu, Ph.D. contact

+86 021-50877628

vivianliu@biomissile.com

Ting Yu contact

+86 021-50877628

tingyu@biomissile.com

China1 site

  • First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui

Other trials in China

About this study

Official title: A Phase Ib/II, Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Combination With PD-1 Inhibitor in Patients With HER2-Related Advanced Solid Tumors

This study is a multicenter, non-randomized, open-label, Phase Ib/II combination therapy trial. The trial consists of two parts: Part 1 (Phase Ib), dose-escalation of combination therapy, followed by Part 2 (Phase II), tumor-type exploration of combination therapy. This study will evaluate the RP2D, safety, tolerability, and preliminary efficacy of BM230 in combination with PD-1 inhibitor in patients with HER2-related solid tumors (including but not limited to colorectal cancer, esophageal squamous cell carcinoma, urothelial carcinoma, cholangiocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, etc.).

Conditions
Solid Tumor
Being tested
BM230 & PD-1 inhibitor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BM230 & PD-1 inhibitorDrug

    BM230: SC injection; PD-1 inhibitor: IV infusion

  • BM230 & PD-1 inhibitorDrug

    BM230: SC injection; PD-1 inhibitor: IV infusion

Study groups in NCT07698587
Study groupRoleWhat they receive
BM230 combined with PD-1 inhibitor: Dose EscalationExperimentalDrug:BM230 Drug:Tislelizumab Injection
Receives: Drug: BM230 & PD-1 inhibitor
BM230 combined with PD-1 inhibitor: Tumor ExplorationExperimentalDrug:BM230 Drug:Tislelizumab Injection
Receives: Drug: BM230 & PD-1 inhibitor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DLT

    Dose limiting toxicity

    Measured: 21 days

  2. AEs

    Adverse events

    Measured: up to 3 years

  3. MTD and/or RP2D

    The maximum tolerated dose (MTD) and/or the recommended phase 2 dose

    Measured: up to 3 years

  4. ORR

    Objective response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  5. DCR

    Disease control rate (DCR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  6. DoR

    Duration of response (DoR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  7. BOR

    Best overall response (BOR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  8. TTR

    Time to response (TTR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  9. PFS

    Progression-free survival (PFS) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  10. OS

    Overall survival (OS) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 3 years

  11. ADA ADA ADA

    Anti-drug antibody

    Measured: up to 3 years

Secondary outcomes (6)

  1. AUC

    area under the concentration-time curve

    Measured: up to 3 years

  2. Cmax

    maximum concentration

    Measured: up to 3 years

  3. Ctrough

    trough concentration

    Measured: up to 3 years

  4. CL

    clearance rate

    Measured: up to 3 years

  5. Vd

    volume of distribution

    Measured: up to 3 years

  6. t1/2

    half-life time

    Measured: up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionDec 2029 (estimated)
  4. Study completionDec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07698587
Sponsor's protocol ID
BM230-02
Status last verified
Jul 2026
First submitted
7 Jul 2026
Last updated
9 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing BM230 & PD-1 inhibitor in people with Solid Tumor, run by Suzhou Biomissile Pharmaceuticals Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rui Liu, Ph.D. (+86 021-50877628, vivianliu@biomissile.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DLT (time frame: 21 days). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07698587.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in